123 related articles for article (PubMed ID: 32452467)
1. Sunitinib-induced pyoderma gangrenosum-like skin ulcer.
Kuntz T; Koushk-Jalali B; Kreuter A
CMAJ; 2020 May; 192(20):E552. PubMed ID: 32452467
[No Abstract] [Full Text] [Related]
2. Pyoderma Gangrenosum Associated with Sunitinib: A Case Report.
Sevimli Dikicier B
Adv Skin Wound Care; 2019 Sep; 32(9):427-429. PubMed ID: 31408027
[TBL] [Abstract][Full Text] [Related]
3. [Sunitinib-induced pyoderma gangrenosum].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2013 Dec; 140(12):841-2. PubMed ID: 24315238
[No Abstract] [Full Text] [Related]
4. A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
Ueharaguchi Y; Kabashima K; Sasahashi M; Matsuda A; Matubara K; Matsui M
Int J Dermatol; 2013 May; 52(5):634-6. PubMed ID: 23590380
[No Abstract] [Full Text] [Related]
5. Pyoderma gangrenosum with the use of sunitinib.
Nadauld LD; Miller MB; Srinivas S
J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
[No Abstract] [Full Text] [Related]
6. Sunitinib induced pyoderma gangrenosum-like ulcerations.
Akanay-Diesel S; Hoff NP; Kürle S; Haes J; Erhardt A; Häussinger D; Schulte KW; Bölke E; Matuschek C; Budach W; Gerber PA; Homey B
Eur J Med Res; 2011 Nov; 16(11):491-4. PubMed ID: 22027642
[TBL] [Abstract][Full Text] [Related]
7. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib?
ten Freyhaus K; Homey B; Bieber T; Wilsmann-Theis D
Br J Dermatol; 2008 Jul; 159(1):242-3. PubMed ID: 18489600
[No Abstract] [Full Text] [Related]
8. Kidney cancer: Intermittent sunitinib is an effective renal carcinoma treatment.
Czarnecka AM
Nat Rev Urol; 2017 May; 14(5):264-266. PubMed ID: 28266515
[No Abstract] [Full Text] [Related]
9. Nonthrombocytopenic, noninflammatory simplex purpura during sunitinib therapy.
García-Legaz Martínez M; Martínez-Doménech Á; Pérez-Pastor G; Magdaleno-Tapial J; Valenzuela-Oñate C; Alegre-de Miquel V; Pérez-Ferriols A
Int J Dermatol; 2019 Aug; 58(8):e153-e155. PubMed ID: 30957224
[No Abstract] [Full Text] [Related]
10. Sunitinib therapy as a cause of diffuse digestive tract hemorrhage in end-stage renal disease patient.
Taki Y; Imai N; Kojima S; Kaneshiro N; Shibagaki Y
Saudi J Kidney Dis Transpl; 2018; 29(2):483-484. PubMed ID: 29657229
[No Abstract] [Full Text] [Related]
11. Imatinib induced pyoderma gangrenosum.
Pinato DJ; Sharma R
J Postgrad Med; 2013; 59(3):244-5. PubMed ID: 24029213
[No Abstract] [Full Text] [Related]
12. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
Cai W; Cai B; Zhou J; Chen Y; Zhang J; Huang Y; Xue W; Huang J
Cancer Commun (Lond); 2019 Oct; 39(1):56. PubMed ID: 31601263
[No Abstract] [Full Text] [Related]
13. [First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].
Rexer H; Bedke J
Urologe A; 2017 Mar; 56(3):385-386. PubMed ID: 28246756
[No Abstract] [Full Text] [Related]
14. The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?
Gyawali B; Goldstein DA
JAMA Oncol; 2018 May; 4(5):623-624. PubMed ID: 29522146
[No Abstract] [Full Text] [Related]
15. Renal damage secondary to check-point inhibitors.
Moliz C; Cavero T; Morales E; Gutiérrez E; Alonso M; Praga M
Nefrologia (Engl Ed); 2020; 40(2):206-208. PubMed ID: 31615688
[No Abstract] [Full Text] [Related]
16. Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports.
Khoshnam-Rad N; Gheymati A; Jahangard-Rafsanjani Z
Anticancer Drugs; 2022 Jan; 33(1):e1-e8. PubMed ID: 34282745
[TBL] [Abstract][Full Text] [Related]
17. ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib.
Werbrouck E; Bastin J; Lambrechts D; Verbiest A; Van Brussel T; Lerut E; Machiels JP; Verschaeve V; Richard V; Debruyne PR; Decallonne B; Schöffski P; Bechter O; Wolter P; Beuselinck B
Acta Clin Belg; 2019 Jun; 74(3):180-188. PubMed ID: 29792121
[TBL] [Abstract][Full Text] [Related]
18. Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions.
Sagara R; Kitami A; Nakada T; Iijima M
Int J Dermatol; 2006 Aug; 45(8):1002-3. PubMed ID: 16911406
[No Abstract] [Full Text] [Related]
19. Sunitinib versus sorafenib for patients with advanced renal cell carcinoma with renal impairment before the immune-oncology therapy era.
Takayama T; Kubo T; Yamazaki M; Takeshima S; Komatsubara M; Kameda T; Kamei J; Sugihara T; Fujisaki A; Ando S; Kurokawa S; Fujimura T
Jpn J Clin Oncol; 2019 Dec; 49(12):1164-1171. PubMed ID: 31665407
[TBL] [Abstract][Full Text] [Related]
20. Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial.
Zhao F; Cella D; Manola J; DiPaola RS; Wagner LI; Haas NSB
Support Care Cancer; 2018 Jun; 26(6):1889-1895. PubMed ID: 29274030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
